Compare Ginkgo Bioworks Holdings Inc (DNA) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Expeditors International of Wshngtn Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Expeditors International of Wshngtn Inc trades at $178.25 (market cap $23.31B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 39.5× Ginkgo Bioworks Holdings Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | EXPD | |
|---|---|---|
Market Cap | $590.53M | $23.31B |
Sector | Health | Industrials |
52-Week High | $16.14 | $178.22 |
52-Week Low | $5.48 | $111.37 |
Enterprise Value | $627.78M | $22.56B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
EXPD trades at $175.50, up 2.02% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, revenue growth to $11.07B in 2025, and impressive ROE of 36.59%. Recent dividend payments and positive analyst coverage highlight financial stability, though valuation metrics appear elevated with P/E of 28.35.
Outlook remains positive with earnings momentum and e-commerce tailwinds, but risks include stretched valuation, mixed analyst sentiment (only 12% buy ratings), and economic sensitivity. The stock trades above consensus price target of $159, suggesting limited near-term upside potential despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
